As shown in Figure 1A, abemaciclib, a drug approved for treating HR+/HER2− advanced breast cancer through CDK4/6 inhibition,30 significantly reduced the fluorescence intensity of GFP‐YAP1. This evidence concerns the gene HR and breast carcinoma.